Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance-Reference-Cited by-同舟云学术

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance

Published:2018-06 Issue:3 Volume:16 Page:226-234
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Yang David D.,Mahal Brandon A.,Muralidhar Vinayak,Vastola Marie E.,Boldbaatar Ninjin,Labe Shelby A.,Nezolosky Michelle D.,Orio Peter F.,King Martin T.,Martin Neil E.,Mouw Kent W.,Trinh Quoc-Dien,Nguyen Paul L.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference33 articles.

1. National Comprehensive Cancer Network. Prostate Cancer (Version 2.2017). Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed: March 14, 2017.

2. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy;Zumsteg;Eur Urol,2013

3. Outcomes of active surveillance for men with intermediate-risk prostate cancer;Cooperberg;J Clin Oncol,2011

4. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial;Godtman;Eur Urol,2013

5. Medium-term outcomes of active surveillance for localised prostate cancer;Selvadurai;Eur Urol,2013

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing histology between prostate cognitive fusion targeted biopsy and radical prostatectomy: exploring risk factors of Gleason score upgrading in Chinese patients;Journal of Cancer Research and Clinical Oncology;2023-11-18

2. Risk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance;Journal of Urology;2023-07

3. Active surveillance for intermediate-risk prostate cancer;World Journal of Urology;2022-01

4. Pathologic upgrading in favorable intermediate risk active surveillance patients: Clinical heterogeneity and implications for active surveillance decision;Urologic Oncology: Seminars and Original Investigations;2021-11

5. ARRDC4 and UBXN1: Novel Target Genes Correlated with Prostate Cancer Gleason Score;Cancers;2021-10-17